Literature DB >> 24581543

Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.

Seiji Matsumoto1, Masaki Watanabe2, Kazumi Hashizume2, Naoki Wada2, Jun-ichi Hori2, Masafumi Kita2, Tatsuya Iwata2, Hidehiro Kakizaki2.   

Abstract

OBJECTIVE: To investigate whether bladder dysfunction after bladder outlet obstruction (BOO) could be altered by treatment with cilostazol, a phosphodiesterase 3 inhibitor (PDE3i).
METHODS: Twelve-week-old female Sprague-Dawley rats were divided into 5 groups: groups 1 and 2, sham-operated rats and groups 3-5, BOO rats. Group 1 and 3 rats were given normal diet, group 2 and 5 rats were given high-dose PDE3i diet, and group 4 rats were given low-dose PDE3i diet. PDE3i was given within diet from the day of surgery. Four weeks after BOO, the bladder was excised and dissected into 4 longitudinal strips for isometric organ-bath assay. Contractile responses of bladder strips to electrical field stimulation (EFS), carbachol, and potassium chloride (KCl) were determined for each group.
RESULTS: BOO induced a significant increase in bladder weight in groups 3-5 compared with groups 1 and 2. PDE3i treatment did not affect bladder weight in sham or BOO rats. Contractile forces in response to EFS, carbachol, and KCl in group 3 were about 20%-40% of those in group 1. Contractile responses to EFS or KCl in PDE3i-treated BOO rats were not significantly different from those in group 3. Only high dose of PDE3i treatment in BOO rats caused a statistically significant increase in the response to carbachol compared with group 3.
CONCLUSION: PDE3i has a small but significant protective effect on the contractile dysfunction induced by a 4-week BOO in rats, although the increase in bladder mass was not altered. PDE3i could be a useful protection against contractile dysfunction of the obstructed bladder.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24581543     DOI: 10.1016/j.urology.2013.11.030

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Sulforaphane Ameliorates Bladder Dysfunction through Activation of the Nrf2-ARE Pathway in a Rat Model of Partial Bladder Outlet Obstruction.

Authors:  Chong Liu; Huan Xu; Shi Fu; Yanbo Chen; Qi Chen; Zhikang Cai; Juan Zhou; Zhong Wang
Journal:  Oxid Med Cell Longev       Date:  2016-06-28       Impact factor: 6.543

2.  Effect of Sulforaphane on Bladder Compliance in a Rat Model of Partial Bladder Outlet Obstruction.

Authors:  Chong Liu; Xiang Wan; Meng Gu; Yanbo Chen; Zhikang Cai; Juan Zhou; Qi Chen; Zhong Wang
Journal:  Oxid Med Cell Longev       Date:  2019-06-18       Impact factor: 6.543

3.  Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.

Authors:  Brian M Balog; Abhilasha Tangada; Pooja Sheth; Qi-Xiang Song; Bruna M Couri; Leah L Porras; Gary G Deng; Margot S Damaser
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

4.  Epigallocatechin Gallate Attenuates Bladder Dysfunction via Suppression of Oxidative Stress in a Rat Model of Partial Bladder Outlet Obstruction.

Authors:  Meng Gu; Chong Liu; Xiang Wan; Tianye Yang; Yanbo Chen; Juan Zhou; Qi Chen; Zhong Wang
Journal:  Oxid Med Cell Longev       Date:  2018-07-22       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.